$BRKR
BRUKER CORP

2022 Q1 Form 10-Q Financial Statement

#000095017022008094 Filed on May 06, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $595.0M $554.7M
YoY Change 7.27% 30.83%
Cost Of Revenue $288.7M $276.0M
YoY Change 4.6% 19.12%
Gross Profit $306.3M $278.7M
YoY Change 9.9% 44.93%
Gross Profit Margin 51.48% 50.24%
Selling, General & Admin $145.7M $131.8M
YoY Change 10.55% 8.75%
% of Gross Profit 47.57% 47.29%
Research & Development $56.60M $54.80M
YoY Change 3.28% 12.99%
% of Gross Profit 18.48% 19.66%
Depreciation & Amortization $21.70M $22.30M
YoY Change -2.69% 17.37%
% of Gross Profit 7.08% 8.0%
Operating Expenses $209.8M $189.6M
YoY Change 10.65% 7.79%
Operating Profit $96.50M $89.10M
YoY Change 8.31% 443.29%
Interest Expense -$2.500M -$3.800M
YoY Change -34.21% 100.0%
% of Operating Profit -2.59% -4.26%
Other Income/Expense, Net -$2.500M -$3.800M
YoY Change -34.21% 31.03%
Pretax Income $94.00M $85.30M
YoY Change 10.2% 531.85%
Income Tax $31.90M $27.50M
% Of Pretax Income 33.94% 32.24%
Net Earnings $61.60M $56.70M
YoY Change 8.64% 440.0%
Net Earnings / Revenue 10.35% 10.22%
Basic Earnings Per Share $0.41 $0.37
Diluted Earnings Per Share $0.41 $0.37
COMMON SHARES
Basic Shares Outstanding 150.4 151.8
Diluted Shares Outstanding 151.4 153.2

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $916.1M $746.8M
YoY Change 22.67% -12.32%
Cash & Equivalents $816.1M $700.4M
Short-Term Investments $100.0M $50.00M
Other Short-Term Assets $181.0M $172.7M
YoY Change 4.81% -7.79%
Inventory $739.9M $700.7M
Prepaid Expenses
Receivables $413.8M $326.0M
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.251B $1.946B
YoY Change 15.65% -2.2%
LONG-TERM ASSETS
Property, Plant & Equipment $403.8M $384.1M
YoY Change 5.13% 20.56%
Goodwill $384.3M
YoY Change
Intangibles $227.5M
YoY Change
Long-Term Investments
YoY Change
Other Assets $284.3M $177.9M
YoY Change 59.81%
Total Long-Term Assets $1.300B $1.089B
YoY Change 19.4% 12.02%
TOTAL ASSETS
Total Short-Term Assets $2.251B $1.946B
Total Long-Term Assets $1.300B $1.089B
Total Assets $3.551B $3.035B
YoY Change 17.0% 2.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $161.2M $152.3M
YoY Change 5.84% 19.92%
Accrued Expenses
YoY Change
Deferred Revenue $214.7M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $11.00M $108.4M
YoY Change -89.85% 13.15%
Total Short-Term Liabilities $880.5M $943.5M
YoY Change -6.68% 23.2%
LONG-TERM LIABILITIES
Long-Term Debt $1.205B $715.8M
YoY Change 68.4% -21.75%
Other Long-Term Liabilities $426.7M $393.9M
YoY Change 8.33% 26.09%
Total Long-Term Liabilities $1.632B $1.110B
YoY Change 47.08% -9.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $880.5M $943.5M
Total Long-Term Liabilities $1.632B $1.110B
Total Liabilities $2.513B $2.067B
YoY Change 21.55% 3.72%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $925.9M
YoY Change
Treasury Stock Shares $25.75M
Shareholders Equity $1.017B $967.7M
YoY Change
Total Liabilities & Shareholders Equity $3.551B $3.035B
YoY Change 17.0% 2.46%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income $61.60M $56.70M
YoY Change 8.64% 440.0%
Depreciation, Depletion And Amortization $21.70M $22.30M
YoY Change -2.69% 17.37%
Cash From Operating Activities $77.80M $98.00M
YoY Change -20.61% 180.0%
INVESTING ACTIVITIES
Capital Expenditures $19.00M $24.70M
YoY Change -23.08% 100.81%
Acquisitions $83.80M $4.000M
YoY Change 1995.0% -81.82%
Other Investing Activities -$82.80M $700.0K
YoY Change -11928.57% -101.0%
Cash From Investing Activities -$101.8M -$24.00M
YoY Change 324.17% -76.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $102.5M $31.50M
YoY Change 225.4% 5150.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -217.4M -38.10M
YoY Change 470.6% -119.92%
NET CHANGE
Cash From Operating Activities 77.80M 98.00M
Cash From Investing Activities -101.8M -24.00M
Cash From Financing Activities -217.4M -38.10M
Net Change In Cash -252.1M 14.90M
YoY Change -1791.95% -87.26%
FREE CASH FLOW
Cash From Operating Activities $77.80M $98.00M
Capital Expenditures $19.00M $24.70M
Free Cash Flow $58.80M $73.30M
YoY Change -19.78% 222.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
53200000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
40700000
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001109354
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
000-30833
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
BRUKER CORPORATION
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3110160
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
40 Manning Road
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Billerica
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01821
CY2022Q1 dei City Area Code
CityAreaCode
978
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
663-3660
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2022Q1 dei Trading Symbol
TradingSymbol
BRKR
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
149255424
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
816100000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1068200000
CY2022Q1 us-gaap Short Term Investments
ShortTermInvestments
100000000.0
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
100000000.0
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
413800000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
416900000
CY2022Q1 us-gaap Inventory Net
InventoryNet
739900000
CY2021Q4 us-gaap Inventory Net
InventoryNet
710100000
CY2022Q1 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
0
CY2022Q1 us-gaap Assets Current
AssetsCurrent
2250800000
CY2021Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
4400000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
2471800000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
403800000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
406100000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
220800000
CY2022Q1 us-gaap Assets
Assets
3550700000
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
181000000.0
CY2021Q4 us-gaap Assets
Assets
3650000000.0
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
172200000
CY2022Q1 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
11000000.0
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
112400000
CY2022Q1 us-gaap Goodwill
Goodwill
384300000
CY2021Q4 us-gaap Goodwill
Goodwill
339500000
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
227500000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
211800000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
284300000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
161200000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
147400000
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
214700000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
197500000
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
493600000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
481200000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
880500000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
938500000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1205400000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1221800000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
426700000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
404900000
CY2022Q1 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
6800000
CY2021Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
200000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
260000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
260000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
175046105
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
174905035
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
149291702
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
150753687
CY2022Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1700000
CY2021Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1700000
CY2022Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
25754403
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
24151348
CY2022Q1 us-gaap Treasury Stock Value
TreasuryStockValue
925900000
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
820300000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-17100000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8200000
CY2022Q1 brkr Other Shareholders Equity
OtherShareholdersEquity
1958300000
CY2021Q4 brkr Other Shareholders Equity
OtherShareholdersEquity
1897300000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1017000000.0
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1070500000
CY2022Q1 us-gaap Minority Interest
MinorityInterest
14300000
CY2021Q4 us-gaap Minority Interest
MinorityInterest
14100000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1031300000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1084600000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3550700000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3650000000.0
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
595000000.0
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
554700000
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
288700000
CY2021Q1 us-gaap Cost Of Revenue
CostOfRevenue
276000000.0
CY2022Q1 us-gaap Gross Profit
GrossProfit
306300000
CY2021Q1 us-gaap Gross Profit
GrossProfit
278700000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
145700000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
131800000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56600000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54800000
CY2022Q1 us-gaap Other Nonrecurring Expense
OtherNonrecurringExpense
7500000
CY2021Q1 us-gaap Other Nonrecurring Expense
OtherNonrecurringExpense
3000000.0
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
209800000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
189600000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
96500000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
89100000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2500000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3800000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
94000000.0
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
85300000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31900000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
27500000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
62100000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
57800000
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
500000
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1100000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
61600000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
56700000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.37
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.41
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
151.4
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.37
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
150.4
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
151.8
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
153.2
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
53200000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
41600000
CY2022Q1 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
200000
CY2021Q1 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
900000
CY2022Q1 brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
-0.2
CY2021Q1 brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
0
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
53200000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
40700000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1084600000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3100000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3800000
CY2022Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
105600000
CY2022Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2022Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7500000
CY2022Q1 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
62100000
CY2022Q1 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
-9200000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1031300000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
974300000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1200000
CY2021Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-100000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3400000
CY2021Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
32800000
CY2021Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.04
CY2021Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
6100000
CY2021Q1 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
57800000
CY2021Q1 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
-16000000.0
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
981700000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
62100000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
57800000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21700000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
22300000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
8000000.0
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3800000
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-4000000.0
CY2021Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
4900000
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
6200000
CY2021Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-4900000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2400000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-800000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
49000000.0
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
41600000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
77800000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
98000000.0
CY2022Q1 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
12000000.0
CY2021Q1 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
0
CY2022Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
83800000
CY2021Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
4000000.0
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-100000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
35500000
CY2022Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
600000
CY2021Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
10100000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
22700000
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
14100000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
22600000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2500000
CY2022Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-1800000
CY2021Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
17100000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19000000.0
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24700000
CY2022Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
12700000
CY2021Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1200000
CY2022Q1 us-gaap Payments For Proceeds From Hedge Investing Activities
PaymentsForProceedsFromHedgeInvestingActivities
-300000
CY2021Q1 us-gaap Payments For Proceeds From Hedge Investing Activities
PaymentsForProceedsFromHedgeInvestingActivities
-3500000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-101800000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24000000.0
CY2022Q1 us-gaap Proceeds From Repayments Of Other Debt
ProceedsFromRepaymentsOfOtherDebt
-400000
CY2021Q1 us-gaap Proceeds From Repayments Of Other Debt
ProceedsFromRepaymentsOfOtherDebt
-100000
CY2022Q1 brkr Repayment Of Two Thousand Twelve Notes Purchase Agreement
RepaymentOfTwoThousandTwelveNotesPurchaseAgreement
-105000000.0
CY2021Q1 brkr Repayment Of Two Thousand Twelve Notes Purchase Agreement
RepaymentOfTwoThousandTwelveNotesPurchaseAgreement
0
CY2022Q1 brkr Repayment Of Two Thousand Nineteen Notes Purchase Agreement
RepaymentOfTwoThousandNineteenNotesPurchaseAgreement
-800000
CY2021Q1 brkr Repayment Of Two Thousand Nineteen Notes Purchase Agreement
RepaymentOfTwoThousandNineteenNotesPurchaseAgreement
0
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3100000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1100000
CY2022Q1 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
1200000
CY2021Q1 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
400000
CY2022Q1 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
7500000
CY2021Q1 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
6100000
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
105600000
CY2021Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
32600000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-217400000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-38100000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-10700000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-21000000.0
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-252100000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14900000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1071700000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
685500000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
819600000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
700400000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3500000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3700000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3500000
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3600000
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
<div style="text-indent:0.0%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Description of Business </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Bruker Corporation, together with its consolidated subsidiaries (Bruker or the Company), develops, manufactures and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. Many of the Company’s products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. The Company’s products address the rapidly evolving needs of a diverse array of customers in life science research, pharmaceuticals, biotechnology, applied markets, cell biology, clinical research, microbiology, in vitro diagnostics, nanotechnology and materials science research.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">four</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> operating segments, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Bruker BioSpin Group, Bruker CALID Group, Bruker Scientific Instruments (BSI) Nano Segment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Bruker Energy &amp; Supercon Technologies (BEST)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> reportable segments, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">BSI Life Science, BSI Nano, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">BEST</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">For financial reporting purposes, the Bruker BioSpin Group and Bruker CALID Group operating segments are aggregated into the reportable BSI Life Science segment because each has similar economic characteristics, production processes, service offerings, types and classes of customers, methods of distribution and regulatory environments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Bruker BioSpin</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> — The Bruker BioSpin Group designs, manufactures and distributes enabling life science tools based on magnetic resonance technology. Bruker BioSpin Group’s revenues are generated by academic and government research customers, pharmaceutical and biotechnology companies and nonprofit laboratories, as well as chemical, food and beverage, clinical and other industrial companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Bruker CALID (Chemicals, Applied Markets, Life Science, In Vitro Diagnostics, Detection)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> — The Bruker CALID Group designs, manufactures and distributes life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies and radiological/nuclear detectors for Chemical, Biological, Radiological, Nuclear and Explosive (CBRNE) detection. Customers of the Bruker CALID Group include academic institutions and medical schools; pharmaceutical, biotechnology and diagnostics companies; contract research organizations; nonprofit and for-profit forensics laboratories; agriculture, food and beverage safety laboratories; environmental and clinical microbiology laboratories; and hospitals and government departments and agencies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The BSI Nano segment designs, manufactures and distributes advanced X-ray instruments; atomic force microscopy instrumentation; advanced fluorescence optical microscopy instruments; analytical tools for electron microscopes and X-ray metrology; defect-detection equipment for semiconductor process control; handheld, portable and mobile X-ray fluorescence spectrometry instruments; spark optical emission spectroscopy systems; chip cytometry products and services for targeted spatial proteomics, multi-omic services; and products and services for spatial genomics research. Customers of the BSI Nano segment include academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies and other businesses involved in materials research and life science research analysis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The BEST reportable segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and “big science” research. The segment focuses on metallic low temperature superconductors for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The unaudited condensed consolidated financial statements represent the consolidated accounts of the Company. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements as of March 31, 2022 and December 31, 2021, and for the three months ended March 31, 2022 and 2021, have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, the financial information presented herein does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair statement have been included. The results for interim periods are not necessarily indicative of the results expected for any other interim period or the full year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">At March 31, 2022, the Company’s significant accounting policies, which are detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, have not changed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks &amp; Uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common to its industry including, but not limited to, global economic conditions, (including increasing inflation), rapid technological change, government and academic funding levels, the impact of the COVID-19 coronavirus, geopolitical uncertainties, changes in commodity prices, spending patterns of its customers, protection of its intellectual property, availability of key raw materials and components, compliance with existing and future regulation by government agencies and fluctuations in foreign currency exchange rates and interest rates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The impact of the COVID-19 worldwide pandemic has been and will likely continue to be extensive in certain geographies and aspects of society. The pandemic has resulted in and will likely continue to result in significant disruptions to the global economy, global supply chains, as well as businesses and capital markets around the world.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Impacts to the Company’s business since the beginning of the pandemic have included temporary closures of many of the Company’s government and university customers and suppliers, disruptions or restrictions on employees’ and customers’ ability to travel, and delays in product installations or shipments to and from affected countries. In an effort to halt the outbreak of COVID-19, a number of countries, including the United States, implemented and some continue to implement, significant restrictions on travel, shelter in place or stay at home orders, and business closures. While many of these restrictions have loosened in certain jurisdictions, including the United States and Europe, some markets have returned and others may return to restrictions in the face of increases in new COVID-19 cases, particularly if additional or more contagious strains of the virus emerge. Many of the Company's employees in jurisdictions in which it has significant operations continue to work remotely. In addition, certain Asia Pacific geographies where the Company operates are continuing to experience significant COVID-19 disruptions, including extensive and sustained lockdowns. Much of the commercial activity in sales and marketing, and customer demonstrations and applications training, is still either being conducted remotely or postponed. Even where customers have re-opened their sites, some still operate at productivity levels that are below pre-pandemic levels in an effort to accommodate safety protocols and as a result of pandemic-related supply chain disruptions. Any resurgence of the virus or the emergence of new strains of the virus, particularly any new strains which are more easily transmitted or which are resistant to existing vaccines, may require the Company or its customers to close or partially close operations once again. These travel restrictions, business closures and operating reductions at Bruker, customers, distributors, and/or suppliers have in the past adversely impacted and may continue to adversely impact the Company’s operations worldwide, including the ability to manufacture, sell or distribute products, as well as cause temporary closures of foreign distributors, or the facilities of suppliers or customers. Global supply chains, including for semiconductor chips, components and raw materials such as copper, have been disrupted, causing shortages, which has impacted the Company’s ability to manufacture or supply its products. The Company could also experience increased compensation expenses associated with employee recruiting and employee retention to the extent employment opportunities continue to multiply post-pandemic, causing the search for and retention of talent to become more competitive. This disruption of the Company’s employees, distributors, suppliers and customers has historically impacted and may continue to impact the Company’s global sales and operating results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Further, while the Company is not currently subject to any vaccine mandate, any requirement to mandate COVID-19 vaccination of its workforce or require the Company’s unvaccinated employees to be tested weekly could result in employee attrition and difficulty securing future labor needs and may have an adverse effect on future operations. It continues to be the Company's policy to encourage each of its employees to be fully vaccinated against COVID-19.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company is continuing to monitor and assess the effects of the COVID-19 pandemic on commercial operations in 2022. However, the Company cannot at this time accurately predict what effects these conditions will ultimately have on future operations due to uncertainties relating to the duration of the outbreak, including the impact of any resurgence of the virus or the continued emergence of new strains of the virus, the effectiveness and availability of vaccines, (including to protect against any new strains of the virus), the willingness of individuals to receive vaccines and boosters, and the length or severity of travel restrictions, business closures and other safety and precautionary measures imposed by the governments of impacted countries. The pandemic has also adversely affected the economies and financial markets of many countries, which has affected and likely will continue to affect demand for the Company's products and its operating results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has experienced supply chain interruptions as a result of the COVID-19 pandemic, general global economic conditions, a tighter labor market and other factors including natural events and disasters. Various factors, including increased demand for certain components and production delays, are contributing to shortages of certain components used in the Company’s products and increased difficulties in the Company’s ability to obtain a consistent supply of materials at stable pricing levels. Supply shortages and longer lead times for components used in the Company’s products, including limited source components, can result in significant additional costs and inefficiencies in manufacturing. A shortage of key components may cause a significant disruption to the Company’s production activities, which could have a substantial adverse effect on the Company’s financial condition or results of operations. If the Company is unsuccessful in resolving any such component shortages in a timely manner, the Company could experience a significant adverse impact on the timing of its revenue, a possible loss of revenue, or an increase in manufacturing costs, any of which could have a material adverse impact on the Company’s operating results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Additionally, geopolitical tensions, such as Russia's ongoing incursion into Ukraine, ongoing conflicts between the United States and China, tariff and trade policy changes, economic sanctions, and increasing potential of conflict involving countries in Asia that are critical to the Company's supply chain operations, such as Taiwan and China, have resulted in increasing global tensions and create uncertainty for global commerce. In addition to experiencing adverse economic impacts resulting from economic sanctions on Russia, the Company has largely suspended its' Russian operations. Sustained or worsening global economic conditions and increasing inflation and geopolitical tensions have increased the Company's cost of doing business, materially disrupted the Company's supply chain operations, caused certain of the Company's customers to reduce or delay spending and further intensified pricing pressures. Any or all of these factors could negatively affect demand for the Company's products and its business, financial condition and result of operations.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the unaudited condensed consolidated financial statements requires the Company to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis the Company evaluates estimates, judgments and methodologies. Changes in estimates are recorded in the period in which they become known. The Company bases estimates on historical experience and on various other assumptions that they believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic, global supply chain interruptions, and geopolitical instability will directly or indirectly impact future business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new developments concerning the COVID-19 pandemic, global supply chain and various global conflicts. The Company has made estimates of the impact of COVID-19 within the financial statements and there may be changes to those estimates in future periods. Actual results may differ from management’s estimates if these results differ from historical experience.</span>
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
4
CY2022Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
595000000.0
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
554700000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
595000000.0
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
554700000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
595000000.0
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
554700000
CY2022Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
2114900000
CY2022Q1 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.74
CY2022Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2022Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
46400000
CY2021Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
46100000
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
467900000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
430800000
CY2021 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
126000000.0
CY2022Q1 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
9800000
CY2022Q1 brkr Payments To Acquire Businesses Cash Acquired
PaymentsToAcquireBusinessesCashAcquired
8300000
CY2022Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
238800000
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
218700000
CY2022Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
266300000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
254900000
CY2022Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
145300000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
144900000
CY2022Q1 us-gaap Other Inventory Demo
OtherInventoryDemo
89500000
CY2021Q4 us-gaap Other Inventory Demo
OtherInventoryDemo
91600000
CY2022Q1 us-gaap Inventory Net
InventoryNet
739900000
CY2021Q4 us-gaap Inventory Net
InventoryNet
710100000
CY2022Q1 us-gaap Other Inventory In Transit
OtherInventoryInTransit
54400000
CY2021Q4 us-gaap Other Inventory In Transit
OtherInventoryInTransit
49500000
CY2021Q4 us-gaap Goodwill
Goodwill
339500000
CY2022Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
50100000
CY2022Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-5300000
CY2022Q1 us-gaap Goodwill
Goodwill
384300000
CY2022Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
506200000
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
278700000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
227500000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
483800000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
272000000.0
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
211800000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9200000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8900000
CY2022Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
1900000
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
2000000.0
CY2022Q1 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
1212300000
CY2021Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
1329900000
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
1216400000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
1334200000
CY2022Q1 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
11000000.0
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
112400000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1205400000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1221800000
CY2022Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
710.3
CY2022Q1 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
110.4
CY2022Q1 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
599.9
CY2022Q1 brkr Decrease In Net Interest Expense Due To Derivative Instruments
DecreaseInNetInterestExpenseDueToDerivativeInstruments
1100000
CY2021Q1 brkr Decrease In Net Interest Expense Due To Derivative Instruments
DecreaseInNetInterestExpenseDueToDerivativeInstruments
1400000
CY2021Q4 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
-51600000
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
20900000
CY2022Q1 us-gaap Derivative Notional Amount
DerivativeNotionalAmount
1343400000
CY2022Q1 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
-20800000
CY2021Q4 us-gaap Derivative Notional Amount
DerivativeNotionalAmount
1524800000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31900000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
27500000
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.339
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.322
CY2022Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
50900000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
51400000
CY2022Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
3500000
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
3100000
CY2022Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
400000
CY2021Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
100000
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.052
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
61600000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
56700000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
150.4
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
151.8
CY2022Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1.0
CY2021Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1.4
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
151.4
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
153.2
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.37
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.41
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.37
CY2022Q1 us-gaap Profit Loss
ProfitLoss
62100000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
57800000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-30500000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-68000000.0
CY2022Q1 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent
21100000
CY2021Q1 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent
48500000
CY2022Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
500000
CY2021Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
3300000
CY2022Q1 brkr Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest And Redeemable Noncontrolling Interest
ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAndRedeemableNoncontrollingInterest
53200000
CY2021Q1 brkr Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest And Redeemable Noncontrolling Interest
ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAndRedeemableNoncontrollingInterest
41600000
CY2022Q1 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
200000
CY2021Q1 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
900000
CY2022Q1 brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
-0.2
CY2021Q1 brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
0
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3800000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3400000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2700000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2022Q1 us-gaap Information Technology And Data Processing
InformationTechnologyAndDataProcessing
1000000.0
CY2021Q1 us-gaap Information Technology And Data Processing
InformationTechnologyAndDataProcessing
700000
CY2022Q1 us-gaap Professional Fees
ProfessionalFees
400000
CY2021Q1 us-gaap Professional Fees
ProfessionalFees
100000
CY2022Q1 brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
300000
CY2021Q1 brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
1300000
CY2022Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
5100000
CY2021Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
900000
CY2022Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
400000
CY2021Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q1 brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
300000
CY2021Q1 brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
0
CY2022Q1 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
7500000
CY2021Q1 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
3000000.0
CY2022Q1 us-gaap Restructuring Charges
RestructuringCharges
400000
CY2021Q1 us-gaap Restructuring Charges
RestructuringCharges
2400000
CY2021Q4 us-gaap Restructuring Reserve
RestructuringReserve
6400000
CY2022Q1 us-gaap Restructuring Charges
RestructuringCharges
400000
CY2022Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
2800000
CY2022Q1 us-gaap Restructuring Reserve Translation And Other Adjustment
RestructuringReserveTranslationAndOtherAdjustment
-1400000
CY2022Q1 us-gaap Restructuring Reserve
RestructuringReserve
2600000
CY2022Q1 brkr Material Accruals For Potential Contingencies
MaterialAccrualsForPotentialContingencies
0
CY2021Q4 brkr Material Accruals For Potential Contingencies
MaterialAccrualsForPotentialContingencies
0
CY2022Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
595000000.0
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
554700000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
96500000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
89100000
CY2022Q1 us-gaap Assets
Assets
3550700000
CY2021Q4 us-gaap Assets
Assets
3650000000.0

Files In Submission

Name View Source Status
0000950170-22-008094-index-headers.html Edgar Link pending
0000950170-22-008094-index.html Edgar Link pending
0000950170-22-008094.txt Edgar Link pending
0000950170-22-008094-xbrl.zip Edgar Link pending
brkr-20220331.htm Edgar Link pending
brkr-20220331.xsd Edgar Link pending
brkr-20220331_cal.xml Edgar Link unprocessable
brkr-20220331_def.xml Edgar Link unprocessable
brkr-20220331_htm.xml Edgar Link completed
brkr-20220331_lab.xml Edgar Link unprocessable
brkr-20220331_pre.xml Edgar Link unprocessable
brkr-ex31_1.htm Edgar Link pending
brkr-ex31_2.htm Edgar Link pending
brkr-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending